Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of HIV-DNA and residual viremia levels through week 96 in HIV-infected individuals who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor-based regimen.
Scutari R, Galli L, Alteri C, Poli A, Piermatteo L, Bigoloni A, Perno CF, Lazzarin A, Ceccherini-Silberstein F, Castagna A, Santoro MM, Gianotti N. Scutari R, et al. Among authors: bigoloni a. Int J Antimicrob Agents. 2023 May;61(5):106771. doi: 10.1016/j.ijantimicag.2023.106771. Epub 2023 Mar 3. Int J Antimicrob Agents. 2023. PMID: 36870403 Clinical Trial.
Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment.
Spagnuolo V, Cocorullo D, Galli L, Bigoloni A, Galli A, Rubinacci A, Mignogna G, Carbone A, Lazzarin A, Castagna A. Spagnuolo V, et al. Among authors: bigoloni a. J Antimicrob Chemother. 2013 Dec;68(12):2960-3. doi: 10.1093/jac/dkt264. Epub 2013 Jun 27. J Antimicrob Chemother. 2013. PMID: 23812682 No abstract available.
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L, Spagnuolo V, Bigoloni A, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Guaraldi G, Di Giambenedetto S, Borderi M, Gibellini D, Caramatti G, Lazzarin A, Castagna A; MODAt Study Group. Galli L, et al. Among authors: bigoloni a. J Antimicrob Chemother. 2016 Jun;71(6):1637-42. doi: 10.1093/jac/dkw031. Epub 2016 Mar 5. J Antimicrob Chemother. 2016. PMID: 26945711 Clinical Trial.
Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression.
Muccini C, Galli L, Poli A, Carbone A, Maillard M, Giusti MC, Spagnuolo V, Bigoloni A, Guffanti M, Gianotti N, Lazzarin A, Castagna A. Muccini C, et al. Among authors: bigoloni a. J Acquir Immune Defic Syndr. 2018 Dec 15;79(5):617-623. doi: 10.1097/QAI.0000000000001854. J Acquir Immune Defic Syndr. 2018. PMID: 30204718
Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S, Racca S, Galli A, Cinque P, Carini E, Lazzarin A. Castagna A, et al. Among authors: bigoloni a. J Antimicrob Chemother. 2019 Jul 1;74(7):2039-2046. doi: 10.1093/jac/dkz138. J Antimicrob Chemother. 2019. PMID: 31225610
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study).
Mastrangelo A, Burbelo PD, Galli L, Poli A, Alteri C, Scutari R, Muccini C, Spagnuolo V, Caccia R, Turrini F, Bigoloni A, Galli A, Castagna A, Cinque P. Mastrangelo A, et al. Among authors: bigoloni a. J Antimicrob Chemother. 2021 May 12;76(6):1646-1648. doi: 10.1093/jac/dkab060. J Antimicrob Chemother. 2021. PMID: 33693943 Free PMC article. No abstract available.
53 results